Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Anne B. Yates, MD The American Journal of Medicine

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

New-onset Atrial Fibrillation Predicts Heart Failure Progression

The Effect of Smoking on the Risk of Sciatica: A Meta-analysis

Sexuality The American Journal of Medicine

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Unusual Cause of Leg Ulcerations

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Phosphorus and Risk of Renal Failure in Subjects with Normal Renal Function John J. Sim, MD, Simran K. Bhandari, MD, Ning Smith, PhD, Joanie Chung, MS,

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial Yutao Guo,

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Epidemiology of Myelodysplastic Syndromes

Sabina Hunziker, MD, MPH, Jennifer Stevens, MD, MS, Michael D

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Reversal of Overanticoagulation in Very Elderly Hospitalized Patients with an INR above 5.0: 24-Hour INR Response after Vitamin K Administration Eric.

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding Joanna M. Peloquin, MD, Siamak M. Seraj, MD,

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Gout in African Americans

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

When Guidelines Cause Hypertension

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Molly E. Waring, PhD, Jane S

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest Tatjana S. Potpara, MD, PhD, Miroslav.

The Reply The American Journal of Medicine

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Prevalence and Risk Factors for Erectile Dysfunction in the US

Insomnia in the Elderly: Cause, Approach, and Treatment

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

To Reduce Stroke with PFO Closure, Respect the Shunt

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

National Trends in Ambulatory Oral Anticoagulant Use

A Post-cure Complication

The American Journal of Medicine

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Primary Care Management of Skin Abscesses Guided by Ultrasound

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Falls in Older Adults: Risk Assessment, Management and Prevention

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Toward a More Responsible News Media

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Evaluation of the Yale New Haven Readmission Risk Score for Pneumonia in a General Hospital Population Gabrielle Schaefer, MD, Robert El-Kareh, MD, MS,

Presentation transcript:

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti, MD, Deirdre A. Lane, PhD, Gregory Y.H. Lip, MD The American Journal of Medicine Volume 129, Issue 6, Pages 600-607 (June 2016) DOI: 10.1016/j.amjmed.2015.10.001 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Incidence rate of bleeding outcomes according to HAS-BLED, ATRIA, and ORBIT scores. (A) Any clinically relevant bleeding. (B) Major bleeding. ATRIA = Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized Ratio, Elderly, Drugs/alcohol; ORBIT = Outcomes Registry for Better Informed Treatment. The American Journal of Medicine 2016 129, 600-607DOI: (10.1016/j.amjmed.2015.10.001) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Area under the curve for bleeding end points with the 3 bleeding risk scores. (A) Any clinically relevant bleeding. (B) Major bleeding. ATRIA = Anticoagulation and Risk Factors in Atrial Fibrillation; AUC = area under the curve; CI = confidence interval; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized Ratio, Elderly, Drugs/alcohol; ORBIT = Outcomes Registry for Better Informed Treatment; SE = standard error. The American Journal of Medicine 2016 129, 600-607DOI: (10.1016/j.amjmed.2015.10.001) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Any clinically relevant bleeding in relation to tertiles of time to therapeutic range and time in therapeutic range as a continuous variable, by ORBIT and ATRIA scores. (A) Time in therapeutic range by tertiles of time in therapeutic range. (B) Time in therapeutic range as a continuous variable vs ORBIT score. (C) Time in therapeutic range as a continuous variable vs ATRIA score. ATRIA = Anticoagulation and Risk Factors in Atrial Fibrillation; ORBIT = Outcomes Registry for Better Informed Treatment; TTR = time in therapeutic range. The American Journal of Medicine 2016 129, 600-607DOI: (10.1016/j.amjmed.2015.10.001) Copyright © 2016 Elsevier Inc. Terms and Conditions